Truist Financial Corp Reduces Holdings in ACADIA Pharmaceuticals by 7513 Shares
January 31, 2023
Trending News ☀️
ACADIA ($NASDAQ:ACAD) Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. It is a publicly traded company listed on the NASDAQ with its headquarters in San Diego, California. The company is dedicated to transforming the lives of patients suffering from debilitating neurological and related conditions in the US and other parts of the world. Recently, Truist Financial Corp reduced its holdings in ACADIA Pharmaceuticals Inc. by 7513 shares. It is the sixth-largest commercial bank in the United States and the second-largest in the Southeast region. ACADIA Pharmaceuticals Inc. is involved in researching and developing drugs for the treatment of neurological diseases such as Parkinson’s, Alzheimer’s and schizophrenia. This drug is used to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The company also has a strong pipeline of potential therapies in early and late-stage clinical trials. This includes a treatment for Parkinson’s disease dementia (PDD), which is currently in Phase 3 clinical trials.
Additionally, the company is pursuing a number of other treatments for Parkinson’s, Alzheimer’s, schizophrenia, and other CNS disorders. The company’s strong pipeline of potential therapies gives investors confidence that it is on the right track to becoming a leader in the biopharmaceutical industry.
Price History
The media exposure for the company has been largely positive, however on Monday, the stock opened at $19.4 and closed at $19.1, a dip of 1.3%. This was a decrease from the prior closing price of $19.4. The dip in stock prices could be due to the recent news of the reduction in holdings from Truist Financial Corp. Investors were likely concerned that the company’s stock value would not hold up and decided to take their money elsewhere. It is possible that this could have an impact on the company’s short-term financial performance.
The future of ACADIA Pharmaceuticals Inc. is uncertain, however, the current media exposure is largely positive and the stock price remains fairly stable. It is unclear how long this will last, but it appears that investors are still confident in the company’s fundamentals and potential for a bright future. There are still plenty of opportunities for ACADIA Pharmaceuticals to thrive in the future, as long as they can continue to deliver on their promises and maintain a strong financial position. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Acadia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 511.5 | -217.34 | -42.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Acadia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -113.3 | 162.54 | 10.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Acadia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 602.49 | 176.81 | 2.63 |
Key Ratios Snapshot
Some of the financial key ratios for Acadia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.4% | – | -43.4% |
| FCF Margin | ROE | ROA |
| -22.2% | -32.3% | -23.0% |
VI Analysis
ACADIA PHARMACEUTICALS is a low risk investment according to VI Risk Rating. This rating is based on an analysis of the company’s fundamentals and its long-term potential. The company’s financial and business aspects are in good shape and VI App has not detected any major red flags. VI App provides a comprehensive view of the company’s financial performance, allowing investors to make informed decisions. The app also highlights any potential risks and provides insight into the company’s liquidity and debt levels. In the case of ACADIA PHARMACEUTICALS, one risk warning has been detected in the cashflow statement. Registering with VI App can help investors gain a comprehensive overview of the company’s performance and make better investment decisions. Overall, the financial and business fundamentals of ACADIA PHARMACEUTICALS indicate that it is a low-risk investment. Investors can use the VI App to gain valuable insight into the company’s financial performance and make informed decisions. The app also enables investors to check for any possible risks before investing their money. More…
VI Peers
ACADIA Pharmaceuticals Inc is a company that focuses on the development of drugs for the treatment of central nervous system disorders. The company has a number of competitors, including Seagen Inc, Mabion SA, and Sonnet BioTherapeutics Holdings Inc. Each of these companies focuses on the development of drugs for the treatment of different diseases and disorders.
– Seagen Inc ($NASDAQ:SGEN)
Seagen Inc. is a biotechnology company focused on the development and commercialization of cancer therapies. The company’s products include Adcetris, a CD30-directed antibody-drug conjugate, and Tukysa, a small molecule inhibitor of tyrosine kinases. Seagen Inc. has a market cap of $23.95 billion and a return on equity of -14.89%. The company’s products are used to treat a variety of cancers, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
– Mabion SA ($LTS:0QGW)
Mabion is a publicly traded company on the Warsaw Stock Exchange. The company’s market capitalization is $345.53 million as of 2022. The company’s return on equity is 23.01%. Mabion is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases.
– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)
Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of cancer. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML). Sonnet BioTherapeutics is headquartered in New York, New York.
As of 2022, Sonnet BioTherapeutics has a market cap of 5.11M and a Return on Equity of -393.11%. The company’s lead product candidate, SNT-127, is a HER2-targeted ADC in clinical development for the treatment of patients with HER2-positive breast cancer and gastric cancer. The company’s second product candidate, SNT-155, is a CD33-targeted ADC in clinical development for the treatment of patients with acute myeloid leukemia (AML).
Summary
Currently, the company is seeing mostly positive media exposure. For investors considering an investment in ACADIA Pharmaceuticals, it is important to understand the current economic and industry climate, the company’s financial health, and recent performance of its stock. Additionally, it is wise to research the company’s management team, competitive landscape, and product offerings. Investors should also analyze the company’s risk profile and future growth potential before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
